Prostaglandin E2, an immunoactivator

Journal of Pharmacological Sciences

Volumn 112, Issue 1, 2010, Pages 1-5

  Sakata, Daiji ^a   Yao, Chengcan ^a   Narumiya, Shuh ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Dendritic cell; Helper T cell subset; Immune inflammation; PGE receptor subtype

Indexed keywords

ANTIGEN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 23; INTERLEUKIN 6; ONO AE 3208; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN E4 ANTAGONIST; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN SPECIFICITY; CELL DIFFERENTIATION; CONTACT ALLERGY; CROHN DISEASE; DISEASE COURSE; HELPER CELL; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; TH17 CELL; ANIMAL; DENDRITIC CELL; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DENDRITIC CELLS; DINOPROSTONE; HUMANS; SIGNAL TRANSDUCTION;

EID: 75749088574     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09R03CP     Document Type: Review

References (30)

1. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112:1557-1569.
2. H2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13:139-145.
3. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485-517.
4. Ushikubi F, Sugimoto Y, Ichikawa A, Narumiya S. Roles of prostanoids revealed from studies using mice lacking specific prostanoids receptors. J Pharmacol Sci. 2000;83:279-285.
5. Narumiya S. Physiology and pathophysiology of prostanoid receptors. Proc Japan Acad Ser B. 2007;83:296-319.
6. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol. 2002;23:144-150.
7. Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol. 1983;3:295-315.
8. Hasler F, Bluestein HG, Zvaifler NJ, Epstein LB. Analysis of the defects responsible for the impaired regulation of EBV-induced B cell proliferation by rheumatoid arthritis lymphocytes. II. Role of monocytes and the increased sensitivity of rheumatoid arthritis lymphocytes to prostaglandin E. J Immunol 1983;131:768-772.
9. 2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol. 1991;146:108-113.
10. Gold KN, Weyand CM, Goronzy JJ. Modulation of helper T cell function by prostaglandins. Arthritis Rheum. 1994;37:925-933.
11. 2 critically depends on interleukin-2. Eur J Immunol. 1995;25:59-63.
12. Rossi Paccani S, Benagiano M, Capitani N, Zornetta I, Ladant D, Montecucco C, et al. The adenylate cyclase toxins of Bacillus anthracis and Bordetella pertussis promote Th2 cell development by shaping T cell antigen receptor signaling. PLoS Pathog. 2009;5:e1000325.
13. Liu L, Yen JH, Ganea D. A novel VIP signaling pathway in T cells cAMP→protein tyrosine phosphatase (SHP-2?)→JAK2/STAT4→Th1 differentiation. Peptides. 2007;28:1814-1824.
14. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol. Chem. 2007;282:11613-11617.
15. 2 that regulate cellular immune responses in the mouse. J Clin Invest. 2001;108:1229-1235.
16. Grader-Beck T, van Puijenbroek AAFL, Nadler LM, Boussiotis VA. cAMP inhibits both Ras and Rap1 activation in primary human T lymphocytes, but only Ras inhibition correlates with blockade of cell cycle progression. Blood. 2003;101:998-1006.
17. Mustelin T, Tasken K. Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem J. 2003;371:15-27.
18. + T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res. 2006;66:1114-1122.
19. H17 cell expansion. Nat Med. 2009;15:633-640.
20. 2 on the differentiation of murine Foxp3+ T regulatory cells and Th17 cells. Prostaglandin Leukot Essent Fatty Acids. 2009;80:195-200.
21. 2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB J. 2004;18:1318-1320
22. 2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J Immunol. 2008;181:721-735.
23. 2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009;206:535-548.
24. 2 synergistically with interleukin-23 favors human Th17 expansion. Blood. 2008;112:3696-3703.
25. 2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T cells. Eur J Immunol. 2009;39:1301-1312.
26. 2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Aethritis Rheum. 2007;56:2608-2619.
27. 2 in experimental inflammatory bowel disease is mediated through the IL-23→IL-17 axis. J Immunol. 2007;178:8138-8147.
28. Libioulle C, Louis E, Hansoul S, Sandor C, Farnir F, Franchimont D, et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet. 2007;20:e58.
29. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002;109:883-893.
30. Nakase H, Fujiyama Y, Oshitani N, Oga T, Nonomura K, Matsuoka T, et al. Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: A randomized phase II, placebo-controlled trial. Inflamm Bowel Dis. 2009; DOI:10.1002/ibd.21080.